Eli Lilly and Novo Nordisk are reportedly nearing agreements with the White House to significantly reduce the prices of obesity drugs and facilitate Medicare access. The Trump administration is actively negotiating these deals to provide weight-loss medications at more affordable rates, including potential pricing of $149 for some drugs. Stocks for both companies have responded positively to these developments, even as Novo Nordisk experienced a slight decline following comments from President Trump regarding future price cuts. The negotiations signal a pivotal moment for the obesity drug market, with both companies eyeing a competitive edge amid the ongoing discussions.